UK’s National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending Janssen’s Imbruvica (ibrutinib), as a treatment option for adults with chronic lymphocytic leukaemia (CLL).

The treatment will be given for adults who have undergone at least one prior therapy or who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is not suitable.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Every year, around 3,400 people are diagnosed with CLL in the UK and the majority of them affected are above 70 years old.

Janssen UK health economics, market access and reimbursement director Jennifer Lee said: “This is very welcome news for patients with CLL, who will now be entitled to access ibrutinib via routine commissioning, and will in turn, free up much needed resources in the Cancer Drugs Fund.

“Every year, around 3,400 people are diagnosed with CLL in the UK and the majority of them affected are above 70 years old.”

“Janssen is dedicated to ensuring that patients with blood cancer have access to the most effective therapies, and we keenly await a similar positive decision by NICE for patients with mantle cell lymphoma and Waldenström macroglobulinemia, who currently have limited treatment options available to them.”

Ibrutinib is the first in a new class of medicines known as Bruton’s tyrosine kinase (BTK) inhibitors and has been designed to specifically block the BTK protein from causing malignant B-cells to multiply and spread.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FAD recommendation made by NICE was based on the results of multiple trials, including RESONATE (PCYC- 1112) and PCYC-1102/3.5.

NICE concluded that ibrutinib represents a cost-effective treatment for patients with CLL and it works by forming a covalent bond with the BTK protein to block the transmission of cell survival signals within the malignant B-cells.